SCHEMBL5370168

SCHEMBL5370168

Cc1ccc2[nH]c3c(c2c1)CCN(C(=O)O)C3

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BAZ2B Q9UIF8 1/20 0.65
LMNA P02545 1/20 0.60
PABPC1 P11940 1/20 0.60
ATM Q13315 1/20 0.60
SMN1; SMN2 Q16637 1/20 0.60
TRPV1 Q8NER1 4/20 0.56
NPC1 O15118 1/20 0.56
CDK4 P11802 4/20 0.55
CCND1 P24385 4/20 0.55
ALDH1A1 P00352 2/20 0.54
GAA P10253 2/20 0.54
MAPT P10636 2/20 0.54
CASP1 P29466 2/20 0.54
CASP7 P55210 2/20 0.54
MEN1 O00255 1/20 0.54
USP2 O75604 1/20 0.54
KMT2A Q03164 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.53
ACHE P22303 4/20 0.52
GRIN1 Q05586 3/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3424575 0.90 BAZ2B (0.81) BAZ2BLMNAPABPC1ATMSMN1; SMN2
SCHEMBL5381266 0.85 TRPV1 (0.69) TRPV1GRIN2B
SCHEMBL3477408 0.84 BAZ2B (0.64) BAZ2BTRPV1ALDH1A1MAPTUSP2
SCHEMBL5375005 0.84 BAZ2B (0.64) BAZ2BTRPV1GAAMAPTCASP1
SCHEMBL5381186 0.84 BAZ2B (0.64) BAZ2BSMN1; SMN2TRPV1CDK4CCND1
SCHEMBL5372790 0.84 BAZ2B (0.67) BAZ2BLMNATRPV1CDK4CCND1
SCHEMBL5376181 0.81 TRPV1 (0.66) TRPV1
SCHEMBL969392 0.81 TRPV1 (0.72) BAZ2BLMNATRPV1CDK4CCND1
SCHEMBL1120507 0.79 L3MBTL1 (0.76) BAZ2BLMNAPABPC1ATMSMN1; SMN2
SCHEMBL12868355 0.79 BAZ2B (1.00) BAZ2BLMNAPABPC1ATMSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1714961-B1 INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2015-12-09 EP claimed
US-20070173537-A1 Indazole compound and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2007-07-26 US claimed
EP-1714961-A1 INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2006-10-25 EP claimed
EP-1714961-B1 INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2015-12-09 EP disclosed
US-20070173537-A1 Indazole compound and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2007-07-26 US disclosed
EP-1714961-A1 INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2006-10-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070173537-A1 Indazole compound and pharmaceutical use thereof CYP3A5, CYP3A43, TP53 BAZ2B 1498/4885LMNA 3390/4885PABPC1 4460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.